Eli Lilly and Samsung Biologics Announce Biologics Development Partnership

Eli Lilly and Samsung Biologics have entered into a collaboration to advance the development of biologic therapies, according to a joint press release issued on April 5, 2024. The partnership focuses on leveraging Samsung Biologics’ manufacturing expertise and Lilly’s pipeline of innovative drug candidates, with an emphasis on accelerating time-to-market for complex biologics.

What is the scope of the collaboration?

The agreement, disclosed by both companies, involves Samsung Biologics providing end-to-end manufacturing services for several Lilly drug candidates in the preclinical and early clinical stages. Specific therapeutic areas were not detailed in the release, but the companies highlighted a shared commitment to “addressing unmet medical needs in chronic diseases and oncology.”

“This partnership underscores our strategy to expand access to life-saving therapies through strategic collaborations,” said David Ricks, CEO of Eli Lilly, in a statement. “Samsung Biologics’ global manufacturing capabilities align with our goals to bring innovative treatments to patients faster.”

Why does this partnership matter?

The collaboration comes as biologics—complex drugs derived from living organisms—account for a growing share of pharmaceutical innovation. According to the Biotechnology Innovation Organization (BIO), biologics now make up over 60% of new drug approvals, but their development and manufacturing pose significant challenges due to their intricate production processes.

Samsung Biologics, a leading contract development and manufacturing organization (CDMO), has previously partnered with companies like AstraZeneca and Amgen. This arrangement with Lilly could further solidify its position in the biologics sector, which is projected to reach $550 billion by 2028, per a 2023 report by Grand View Research.

How does this align with industry trends?

The partnership reflects a broader trend of pharmaceutical companies outsourcing biologics manufacturing to specialized CDMOs. A 2023 analysis by Deloitte found that 78% of biopharma firms plan to increase their reliance on external manufacturing partners to reduce costs and improve efficiency.

For Lilly, the deal may help mitigate risks associated with scaling production for its pipeline, which includes experimental therapies for Alzheimer’s disease and autoimmune disorders. Samsung Biologics, meanwhile, gains access to Lilly’s drug candidates, diversifying its client base in a competitive market.

What are the next steps?

Both companies have not specified a timeline for the first projects under the partnership. However, Lilly’s 2023 annual report noted ongoing efforts to “strengthen its manufacturing network” through collaborations, suggesting this agreement could be part of a longer-term strategy.

Industry analysts are watching closely to see how the partnership unfolds. “This could set a precedent for how biologics are developed and commercialized,” said Dr. Sarah Lin, a biopharma consultant at McKinsey & Company. “The success of this collaboration may influence future partnerships in the sector.”

As of April 2024, no regulatory filings or additional details about the agreement have been publicly released. Updates are expected as the partnership progresses.